NCT01617941 - A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention | Biotech Hunter

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions

Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening

Interventions

DRUG

BGG492

DRUG

Placebo

In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.